Long-term outcome with interstitial brachytherapy in the management of patients with early-stage breast cancer treated with breast-conserving therapy

Vicini, Frank A.; Horwitz, Eric M.; Lacerna, Mario D.; Dmuchowski, Carl; Brown, Douglas M.; White, Julia; Chen, Peter Y.; Edmundson, Gregory K.; Gustafson, Gary; Clarke, Daniel H.; Gustafson, S Gregory S.; Matter, Richard C.; Martínez, Álvaro

doi:10.1016/s0360-3016(96)00606-2

Cited by 46 publications

(20 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, a longer follow-up is needed to evaluate the "late" local recurrence rate. Vicini et al [53] reported on 390 patients who received either electrons, photons or CLDR brachytherapy after breast conserving therapy. More than 90% of the patients obtained good or excellent cosmetic results.…”

Section: Cosmesismentioning

confidence: 99%

5-Year Results of Pulsed Dose Rate Brachytherapy Applied as a Boost after Breast-Conserving Therapy in Patients at High Risk for Local Recurrence from Breast Cancer

Harms

Krempien

Hensley

et al. 2002

Strahlentherapie und Onkologie

View full text Add to dashboard Cite

show abstract

Section: Cosmesismentioning

confidence: 99%

5-Year Results of Pulsed Dose Rate Brachytherapy Applied as a Boost after Breast-Conserving Therapy in Patients at High Risk for Local Recurrence from Breast Cancer

Harms

Krempien

Hensley

et al. 2002

Strahlentherapie und Onkologie

View full text Add to dashboard Cite

show abstract

“…However, generally accepted guidelines for the indication of boost dose are not available in the literature. Further controversy exists regarding the optimal boost technique (electron vs brachytherapy), and their impact on LTC and cosmesis [8,11,21,22,27,36,38,41,48,55,59,61,62]. To date, only limited information has been reported in the literature about the feasibility, efficacy, and late side effects of boost treatments using high-dose-rate brachytherapy (HDR BT) [8, 22-24, 26, 27, 35].…”

Section: Introductionmentioning

confidence: 99%

Electron and High-Dose-Rate Brachytherapy Boost in the Conservative Treatment of Stage I-II Breast Cancer

Polgár

Fodor

Orosz

et al. 2002

Strahlentherapie und Onkologie

145

View full text Add to dashboard Cite

Boost dose significantly improves LTC and RFS in patients treated with BCS and radiotherapy. In spite of the higher incidence of late side effects in the boost arm, boost dose is strongly recommended for patients at high risk for local recurrence. Positive or close margin status, high mitotic activity index, and young patient age should be viewed as absolute indications for tumor bed boost. LTC and cosmesis are excellent and similar to patients boosted with either HDR BT or electrons.

show abstract

“…In our cases, this is not required as majority had sufficient tumour depth to spare skin. For a start-up new radiotherapy centre with Brachytherapy, the following above steps and guidelines as done in our centre if followed, [12][13][14] the failure and complication rate will be very low. Even if a failure occurs we can treat and salvage as if we are treating the case de novo.…”

Section: Discussionmentioning

confidence: 99%

“…Even if a failure occurs we can treat and salvage as if we are treating the case de novo. [8,12,15] In the series presented, we follow the guidelines and select suitable patients only and it will be the reason for encountering no local failure after > 5 years F.U. (for early Breast Cancer this may not be adequate to call long term).…”

Section: Discussionmentioning

confidence: 99%

Interstitial HDR Brachytherapy in BCT: A Case Series Study from a Single Institute

Nirpendra¹,

Singh²,

Sharma³

et al. 2017

Ann. Int. Med. Den. Res.

View full text Add to dashboard Cite

Background: Radiotherapy (RT) plays an integral part in the management of breast cancer. In BCT there is 20% reduction in loco regional failure and 15 years breast cancer mortality reduction by 5% when RT is used as adjuvant therapy. Adjuvant radiation therapy can be delivered by External Beam Radiotherapy (EBRT) with brachytherapy (BT) or BT alone. Aims: Loco regional control of disease with good cosmesis. Primary end point is loco regional failure. Methods: A total of 30 cases of early breast cancers (T1, T2 N0M0) treated during May 2008 to Dec 2012 and followed up till July 2015 were studied. External radiation dose of 45 to 50 Gy by Telecobalt-60 followed by boost implant BT with dose of 15 to 20Gy in 3 to 4 fractions was used (BED = 84.4 ± 1.1 Gy) for combined external plus BT as per departmental protocol. A total of 30 Gy in 6 fractions was used (BED = 47.8 Gy) for BT alone as per departmental protocol. Ir-192 Micro selectron HDR rigid needle template or flexible catheter implant to primary site was used. Dosimetry was done with Plato sunrise treatment planning System. Results: Age ranges from 23 to 50 years. Median follow up was 54 months. None had local recurrence. Only 1 had mild needle wound sepsis and all had good to excellent acceptable cosmetic results. Radiation skin reaction and sub cutaneous fibrosis were grade I and 2. Three had disease recurrence at distant sites and one patient had moderate telangiectasia at the irradiated site. Conclusion: BCT with EBRT and HDR BT boost or HDR BT alone has shown good results in both loco regional control of disease with good to excellent cosmesis.

show abstract

Long-term outcome with interstitial brachytherapy in the management of patients with early-stage breast cancer treated with breast-conserving therapy

Cited by 46 publications

References 32 publications

5-Year Results of Pulsed Dose Rate Brachytherapy Applied as a Boost after Breast-Conserving Therapy in Patients at High Risk for Local Recurrence from Breast Cancer

5-Year Results of Pulsed Dose Rate Brachytherapy Applied as a Boost after Breast-Conserving Therapy in Patients at High Risk for Local Recurrence from Breast Cancer

Electron and High-Dose-Rate Brachytherapy Boost in the Conservative Treatment of Stage I-II Breast Cancer

Interstitial HDR Brachytherapy in BCT: A Case Series Study from a Single Institute

Contact Info

Product

Resources

About